Technische Universitat Munchen

Ingrid Dijkgraaf

Horst Kessler

Oliver Demmer

Hans-Jürgen Wester

Margret Schottelius

Hans Jürgen Wester

Andreas Konard Buck

Andreas Konrad Buck

The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaato Xaaare independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a detectable label; or ii) a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins and combinations thereof, with the proviso that -L-Ar-D does not comprise aF-benzoyl residue.

Cyclopentapeptide derivatives and uses thereof

A compound, or a pharmaceutically acceptable salt or ester thereof, comprises the structure: [(P1-S1)-L-(S2-P2)]wherein: P1 and P2, which may be the same or different, are cyclic oligopeptide moieties, at least one of P1 and P2 having the motif B-Arg or B-(Me) Arg within the cyclic moiety, wherein B is a basic amino acid, a derivative thereof, or phenylalanine or a derivative thereof; S1 and S2 are spacer groups, which may be the same or different; L is a linker moiety containing at least two functional groups for attachment of the cyclic oligopeptides or spacer groups; n and q are independently 0 or 1; p and r are independently integers of 1 or more; and t is an integer of 1 or more, provided that, when t, p or r is greater than 1, the cyclic oligopeptide moiety, spacer group and/or the value of j or q may be the same or different between the multiple (P1-S1) moieties or multiple (S2-P2) moieties.

Cancer imaging and treatment

Growing community of inventors

Kranenburg, Germany

Ingrid Dijkgraaf